Production of Remedial Proteins through Genetically Modified Bacteria

Fatima Tariq, Muhammad Azmat Ullah Khan, Saqib Shahzad, Wajeeha Batool Chaudhary, Amina Arif, Ghazleh Gharib

Abstract


Recombinant DNA technology has created biological organisms with advanced genetic sequences and has been extensively used to express multiple genes for therapeutic purposes when expressed in a suitable host. Microbial systems such as prokaryotic bacteria has been successfully utilized as a heterologous systems showing high therapeutic potency for various human diseases. Bioengineered bacteria have been successfully utilized for producing therapeutic proteins, treating infectious diseases, and disease arise due to increasing resistance to antibiotics. Prominently E. colifound to be the most widely used expression system for recombinant therapeutic protein production i.e. hormones, enzymes and antibodies. Besides E. coli, non-pathogenic lactic acid bacteria has also been considered as an excellent candidate for live mucosal vaccine. Likewise, S. typhimuriumhas been deployed as attenuated type of vaccination as well as in treatment strategy of various cancers due to its ability of wide progression in tumors. The present article is a summarized view of the main achievements and current developments in the field of recombinant therapeutics using bacterial strains focusing on their usability in therapeutics and future potential.  


Full Text:

PDF

References


Gavanji S, Begum M, Newaz AW, Dewan B, Kamal M, et al. Application of recombinant DNA technology—A review. Applied Scientific Report, (2013); 229-31.

Sanchez-Garcia L, Martín L, Mangues R, Ferrer-Miralles N, Vázquez E, et al. Recombinant pharmaceuticals from microbial cells: a 2015 update. Microbial cell factories, (2016); 15(1): 1.

Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M. Viral vectors: a look back and ahead on gene transfer technology. New Microbiol, (2013); 36(1): 1-22.

Lara AR, Ramírez OT. Plasmid DNA production for therapeutic applications. Recombinant Gene Expression, (2012); 271-303.

Gardlik R, Behuliak M, Palffy R, Celec P, Li C. Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene therapy, (2011); 18(5): 425-431.

Powell JS. Lasting power of new clotting proteins. ASH Education Program Book, (2014); 2014(1): 355-363.

Baeshen NA, Baeshen MN, Sheikh A, Bora RS, Ahmed MMM, et al. Cell factories for insulin production. Microbial cell factories, (2014); 13(1): 1.

Corchero JL, Gasser B, Resina D, Smith W, Parrilli E, et al. Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. Biotechnology advances, (2013); 31(2): 140-153.

Demain AL, Vaishnav P. Production of recombinant proteins by microbes and higher organisms. Biotechnology advances, (2009); 27(3): 297-306.

LeBlanc JG, Aubry C, Cortes-Perez NG, de LeBlanc AdM, Vergnolle N, et al. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. FEMS microbiology letters, (2013); 344(1): 1-9.

Chua KJ, Kwok WC, Aggarwal N, Sun T, Chang MW. Designer probiotics for the prevention and treatment of human diseases. Current Opinion in Chemical Biology, (2017); 40(Supplement C): 8-16.

Glenting J, Poulsen LK, Kato K, Madsen SM, Frøkiær H, et al. Production of recombinant peanut allergen Ara h 2 using Lactococcus lactis. Microbial cell factories, (2007); 6(1): 28.

Nguyen VH, Kim H-S, Ha J-M, Hong Y, Choy HE, et al. Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer research, (2010); 70(1): 18-23.

Prodam F, Caputo M, Belcastro S, Garbaccio V, Zavattaro M, et al. Quality of life, mood disturbances and psychological parameters in adult patients with GH deficiency. Panminerva medica, (2012); 54(4): 323.

Kim M-J, Park HS, Seo KH, Yang H-J, Kim S-K, et al. Complete solubilization and purification of recombinant human growth hormone produced in Escherichia coli. PLoS One, (2013); 8(2): e56168.

Nyberg F, Hallberg M. Growth hormone and cognitive function. Nature Reviews Endocrinology, (2013); 9(6): 357-365.

Gurung N, Ray S, Bose S, Rai V. A broader view: microbial enzymes and their relevance in industries, medicine, and beyond. BioMed research international, (2013); 2013: 329121.

Jørgensen CM, Vrang A, Madsen SM. Recombinant protein expression in Lactococcus lactis using the P170 expression system. FEMS microbiology letters, (2014); 351(2): 170-178.

Sriraman K, Jayaraman G. Enhancement of recombinant streptokinase production in Lactococcus lactis by suppression of acid tolerance response. Applied microbiology and biotechnology, (2006); 72(6): 1202-1209.

Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Frontiers in microbiology, (2010); 1: 134.

Hwang IY, Koh E, Kim HR, Yew WS, Chang MW. Reprogrammable microbial cell-based therapeutics against antibiotic-resistant bacteria. Drug Resistance Updates, (2016); 2759-71.

Banin E, Hughes D, Kuipers OP. Editorial: Bacterial pathogens, antibiotics and antibiotic resistance. FEMS Microbiology Reviews, (2017); 41(3): 450-452.

Braff D, Shis D, Collins JJ. Synthetic biology platform technologies for antimicrobial applications. Advanced drug delivery reviews, (2016); 105: 35-43.

Demain AL. Small bugs, big business: the economic power of the microbe. Biotechnology advances, (2000); 18(6): 499-514.

LaSarre B, Federle MJ. Exploiting quorum sensing to confuse bacterial pathogens. Microbiology and Molecular Biology Reviews, (2013); 77(1): 73-111.

Duan F, March JC. Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proceedings of the National Academy of Sciences, (2010); 107(25): 11260-11264.

Sleator RD. Designer probiotics: Development and applications in gastrointestinal health. World journal of gastrointestinal pathophysiology, (2015); 6(3): 73.

Paton AW, Jennings MP, Morona R, Wang H, Focareta A, et al. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology, (2005); 128(5): 1219-1228.

Focareta A, Paton JC, Morona R, Cook J, Paton AW. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology, (2006); 130(6): 1688-1695.

Mandal SM, Silva ON, Franco OL. Recombinant probiotics with antimicrobial peptides: a dual strategy to improve immune response in immunocompromised patients. Drug discovery today, (2014); 19(8): 1045-1050.

Borrero J, Chen Y, Dunny GM, Kaznessis YN. Modified lactic acid bacteria detect and inhibit multiresistant Enterococci. ACS synthetic biology, (2014); 4(3): 299-306.

Volzing K, Borrero J, Sadowsky MJ, Kaznessis YN. Antimicrobial peptides targeting Gram-negative pathogens, produced and delivered by lactic acid bacteria. ACS synthetic biology, (2013); 2(11): 643-650.

Buckner MM, Finlay BB. Host-microbe interaction: innate immunity cues virulence. Nature, (2011); 472(7342): 179-180.

Vangelista L, Secchi M, Liu X, Bachi A, Jia L, et al. Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. Antimicrobial agents and chemotherapy, (2010); 54(7): 2994-3001.

Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal immunology, (2011); 4(6): 648-657.

Rao S, Hu S, McHugh L, Lueders K, Henry K, et al. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proceedings of the National Academy of Sciences of the United States of America, (2005); 102(34): 11993-11998.

Wang S, Curtiss III R. Development of Streptococcus pneumoniae vaccines using live vectors. Vaccines, (2014); 2(1): 49-88.

Gersch ED, Gissmann L, Garcea RL. New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention. Antiviral therapy, (2012); 17(3).

Yoon W, Choi JH, Kim S, Park YK. Engineered Salmonella typhimurium expressing E7 fusion protein, derived from human papillomavirus, inhibits tumor growth in cervical tumor-bearing mice. Biotechnology letters, (2014); 36(2): 349-356.

Kong W, Clark-Curtiss J, Curtiss III R. Utilizing Salmonella for antigen delivery: the aims and benefits of bacterial delivered vaccination. Expert review of vaccines, (2013); 12(4): 345-347.

Kumar M, Yadav AK, Verma V, Singh B, Mal G, et al. Bioengineered probiotics as a new hope for health and diseases: an overview of potential and prospects. Future microbiology, (2016); 11(4): 585-600.

Bermúdez-Humarán LG, Kharrat P, Chatel J-M, Langella P. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microbial cell factories, (2011); 10(1): 1.

Michon C, Langella P, Eijsink V, Mathiesen G, Chatel J. Display of recombinant proteins at the surface of lactic acid bacteria: strategies and applications. Microbial cell factories, (2016); 15(1): 1.

Wyszyńska A, Kobierecka P, Bardowski J, Jagusztyn-Krynicka EK. Lactic acid bacteria—20 years exploring their potential as live vectors for mucosal vaccination. Applied microbiology and biotechnology, (2015); 99(7): 2967-2977.

Kawana K, Adachi K, Kojima S, Taguchi A, Tomio K, et al. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. Vaccine, (2014); 32(47): 6233-6239.

Lee TY, Kim YH, Lee KS, Kim JK, Lee IH, et al. Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice. Cancer immunology, immunotherapy, (2010); 59(11): 1727-1737.

Fredriksen L, Mathiesen G, Sioud M, Eijsink VG. Cell wall anchoring of the 37-kilodalton oncofetal antigen by Lactobacillus plantarum for mucosal cancer vaccine delivery. Applied and environmental microbiology, (2010); 76(21): 7359-7362.

Yoon SW, Lee TY, Kim SJ, Lee IH, Sung MH, et al. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Vaccine, (2012); 30(22): 3286-3294.

Kajikawa A, Satoh E, Leer RJ, Yamamoto S, Igimi S. Intragastric immunization with recombinant Lactobacillus casei expressing flagellar antigen confers antibody-independent protective immunity against Salmonella enterica serovar Enteritidis. Vaccine, (2007); 25(18): 3599-3605.

Wen LJ, Hou XL, Wang GH, Yu LY, Wei XM, et al. Immunization with recombinant Lactobacillus casei strains producing K99, K88 fimbrial protein protects mice against enterotoxigenic Escherichia coli. Vaccine, (2012); 30(22): 3339-3349.

Kajikawa A, Masuda K, Katoh M, Igimi S. Adjuvant effects for oral immunization provided by recombinant Lactobacillus casei secreting biologically active murine interleukin-1β. Clinical and Vaccine Immunology, (2010); 17(1): 43-48.

Zhang H-x, Qiu Y-y, Zhao Y-h, Liu X-t, Liu M, et al. Immunogenicity of oral vaccination with Lactococcus lactis derived vaccine candidate antigen (UreB) of Helicobacter pylori fused with the human interleukin 2 as adjuvant. Molecular and cellular probes, (2014); 28(1): 25-30.

Felgner S, Kocijancic D, Frahm M, Weiss S. Bacteria in cancer therapy: renaissance of an old concept. International journal of microbiology, (2016); 2016: 8451728.

Adnan M, Khan S, Al-Shammari E, Patel M, Saeed M, et al. In pursuit of cancer metastasis therapy by bacteria and its biofilms: History or future. Medical Hypotheses, (2017); 100(Supplement C): 78-81.

Nallar SC, Xu D-Q, Kalvakolanu DV. Bacteria and genetically modified bacteria as cancer therapeutics: Current advances and challenges. Cytokine, (2016): 89; 160-172.

Camacho EM, Mesa-Pereira B, Medina C, Flores A, Santero E. Engineering Salmonella as intracellular factory for effective killing of tumour cells. Scientific Reports, (2016); 6: 30591.

Patyar S, Joshi R, Byrav DP, Prakash A, Medhi B, et al. Bacteria in cancer therapy: a novel experimental strategy. Journal of biomedical science, (2010); 17(1): 1.

Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biologics, (2014); 813-25.

Zu C, Wang J. Tumor-colonizing bacteria: a potential tumor targeting therapy. Critical reviews in microbiology, (2014); 40(3): 225-235.

Liu S, Xu X, Zeng X, Li L, Chen Q, et al. Tumor‑targeting bacterial therapy: A potential treatment for oral cancer (Review). Oncology letters, (2014); 8(6): 2359-2366.

Larsen M, Griesenbach U, Goussard S, Gruenert D, Geddes D, et al. Bactofection of lung epithelial cells in vitro and in vivo using a genetically modified Escherichia coli. Gene therapy, (2008); 15(6): 434-442.

Li Z, Fallon J, Mandeli J, Wetmur J, Woo SL. retraction: A Genetically enhanced Anaerobic Bacterium for oncopathic Therapy of pancreatic Cancer. Journal of the National Cancer Institute, (2010); 102(4): 283-283.




DOI: http://dx.doi.org/10.62940/als.v5i2.451

Refbacks

  • There are currently no refbacks.